Literature DB >> 24183365

Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients.

Jaleh Taeb1, Mojgan Asgari2, Maryam Abolhasani2, Mohammad M Farajollahi3, Zahra Madjd4.   

Abstract

Proteins expressed in prostate cancer, including prostate stem cell antigen (PSCA), have been investigated as biomarkers for diagnosis and therapy of prostate cancer. Immunohistochemical analysis of PSCA expression was performed on tissue microarrays of 185 paraffin-embedded tissues of Iranian patients, including 114 prostate cancers (PCa), 21 High Grade Prostatic Intraepithelial Neoplasias (HGPIN) and 50 samples of benign prostate tissue. The level of PSCA expression was compared between benign tissues, HGPIN and PCa. Then the correlations of PSCA expression with clinicopathologic parameters were assessed in PCa. The PSCA expression was detected in the membrane and cytoplasm of epithelial secretory cells in normal prostate tissues, HGPIN and PCa with a variety of intensities. The intensity of PSCA staining was significantly increased in the PCa group as compared with HGPIN and benign prostate tissues (P-value<0.05). Moreover, the level of PSCA expression was increased with higher Gleason score of PCa (P-value=0.036). The data presented here revealed that expression of PSCA as a cell surface marker increased from benign prostate tissues (BPH) and HGPIN to PCa, and its expression in PCa was positively associated with poor cell differentiation, suggesting that PSCA could be considered as a valuable target for diagnosis and therapy of PCa.
Copyright © 2013 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Diagnosis; PSCA; Prostate cancer; Tissue microarray

Mesh:

Substances:

Year:  2013        PMID: 24183365     DOI: 10.1016/j.prp.2013.09.012

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  9 in total

1.  Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas.

Authors:  Elham Kalantari; Mojgan Asgari; Seyedehmoozhan Nikpanah; Naghme Salarieh; Mohammad Hossein Asadi Lari; Zahra Madjd
Journal:  Pathol Oncol Res       Date:  2017-01-12       Impact factor: 3.201

Review 2.  Prostate cancer relevant antigens and enzymes for targeted drug delivery.

Authors:  Ashutosh Barve; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

Review 3.  Organization, evolution and functions of the human and mouse Ly6/uPAR family genes.

Authors:  Chelsea L Loughner; Elspeth A Bruford; Monica S McAndrews; Emili E Delp; Sudha Swamynathan; Shivalingappa K Swamynathan
Journal:  Hum Genomics       Date:  2016-04-21       Impact factor: 4.639

4.  PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.

Authors:  Sung Han Kim; Weon Seo Park; Bo Ram Park; Jungnam Joo; Jae Young Joung; Ho Kyung Seo; Jinsoo Chung; Kang Hyun Lee
Journal:  Asian J Androl       Date:  2017 Jul-Aug       Impact factor: 3.285

5.  PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.

Authors:  Marie-Christine Heinrich; Cosima Göbel; Martina Kluth; Christian Bernreuther; Charlotte Sauer; Cornelia Schroeder; Christina Möller-Koop; Claudia Hube-Magg; Patrick Lebok; Eike Burandt; Guido Sauter; Ronald Simon; Hartwig Huland; Markus Graefen; Hans Heinzer; Thorsten Schlomm; Asmus Heumann
Journal:  BMC Cancer       Date:  2018-05-31       Impact factor: 4.430

6.  Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis.

Authors:  Xue-Ling Kang; Li-Rui He; Yao-Li Chen; Shu-Bin Wang
Journal:  World J Gastroenterol       Date:  2020-11-21       Impact factor: 5.742

7.  Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.

Authors:  Kun Chang; Yun-Yi Kong; Bo Dai; Ding-Wei Ye; Yuan-Yuan Qu; Yue Wang; Zhong-Wei Jia; Gao-Xiang Li
Journal:  Oncotarget       Date:  2015-12-08

8.  Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

Authors:  Bently P Doonan; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2015-08-26

9.  The Correlation between PSCA Expression and Neuroendocrine Differentiation in Prostate Cancer.

Authors:  Qian Xiang; Zhiguo Zhu; Lianmin Luo; Jiamin Wang; Yangzhou Liu; Yihan Deng; Mingda Zhou; Zhigang Zhao
Journal:  Biomed Res Int       Date:  2020-09-24       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.